Pharmacogenomics of New Antiretrovirals
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02514369 |
Recruitment Status : Unknown
Verified July 2015 by Cliniques universitaires Saint-Luc- Université Catholique de Louvain.
Recruitment status was: Recruiting
First Posted : August 3, 2015
Last Update Posted : August 3, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
HIV |
Study Type : | Observational |
Estimated Enrollment : | 250 participants |
Observational Model: | Cohort |
Time Perspective: | Cross-Sectional |
Official Title: | Pharmacogenetics of New Antiretroviral Drugs |
Study Start Date : | November 2012 |
Estimated Primary Completion Date : | December 2015 |
- Impact of pharmacogenomics on plasma concentration of new antiretroviral drugs [ Time Frame: up to 48 months ]
- Impact of pharmacogenomics on intracellular concentration of new antiretroviral drugs [ Time Frame: up to 48 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- HIV-1 positive treated with drug of interest
Exclusion Criteria:
- <18 years old

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02514369
Contact: Leila Belkhir, MD | 003227647087 | leila.belkhir@uclouvain.be |
Belgium | |
Cliniques universitaires Saint-Luc | Recruiting |
Brussels, Belgium, 1200 | |
Contact: Leila Belkhir, MD 003227647087 leila.belkhir@uclouvain.be | |
Sub-Investigator: Vincent Haufroid, Pharm PhD | |
Sub-Investigator: Bernard Vandercam, MD |
Responsible Party: | Cliniques universitaires Saint-Luc- Université Catholique de Louvain |
ClinicalTrials.gov Identifier: | NCT02514369 History of Changes |
Other Study ID Numbers: |
ARVLB01 |
First Posted: | August 3, 2015 Key Record Dates |
Last Update Posted: | August 3, 2015 |
Last Verified: | July 2015 |
Additional relevant MeSH terms:
Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents |